Pilot study using long acting injectable buprenorphine (LAIB) as a novel treatment option in NHS Lanarkshire Addiction Services in Scotland

Background. Following the recent availability to a new formulation of buprenorphine for use in the treatment of opioid use, NHS Lanarkshire wanted to gain some “real life” experience of the formulation both from the patients' perspective and from that of the clinical staff and addiction teams. Aim. Develop guidance to introduce a pilot study for the use of the Long Acting Injectable Buprenorphine (LAIB) and gain “lived experience” for the use of the product and the benefits for patients. Methods. To prepare a guideline for the use of LAIB and offer a limited pilot study of treatment from a single site in NHS Lanarkshire. Data collection will be through the use of semi structure questionnaires which will be asked to the patients to determine advantages and benefit of this treatment option. Results. The results of the questionnaires use with patients on the pilot study were very positive and additional benefits can be seen from the pilot study, e.g. reduced overdoses, reduced hospital attendances, improved relationships and reduced stigma associated with treatment. Conclusions. This pilot study demonstrated the treatment could be introduced and as a treatment option can be viewed as beneficial for suitable patients.